Back to results
US 2024/0174988 A1Published application
Glycoengineering
AssigneeThe General Hospital Corporation
InventorsRobert M. Anthony, Maya Kitaoka
Life of this patent
Estimating the term…
Abstract
This disclosure relates to glycoengineering, and methods of utilizing glycoengineering for various therapeutic purposes.
Claims21
A fusion polypeptide comprising:
- an antibody heavy chain CH2 region;
- an antibody heavy chain CH3 region;
- and
- a catalytic domain of a sialyltransferase, wherein the catalytic domain of the sialyltransferase catalyzes sialylation of a glycoprotein.
1 more element
A fusion polypeptide comprising:
- an antibody heavy chain CH2 region;
- an antibody heavy chain CH3 region;
- and
- a catalytic domain of galactosyltransferase, wherein the catalytic domain of galactosyltransferase catalyzes galactosylation of a glycoprotein.
1 more element
A heteromultimer comprising
- a first fusion polypeptide comprising an antibody heavy chain CH2 region, an antibody heavy chain CH3 region, and a catalytic domain of sialyltransferase, wherein the catalytic domain of sialyltransferase catalyzes sialylation of a glycoprotein;
- and
- a second fusion polypeptide comprising an antibody heavy chain CH2 region, an antibody heavy chain CH3 region, and a catalytic domain of galactosyltransferase, wherein the catalytic domain of galactosyltransferase catalyzes galactosylation of a glycoprotein.
21-51. (canceled)
Dependencies are inferred from the claim text.